Plain-English translation of NCT05747625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new diagnostic tool called 89Zr paired with a special imaging scan (PET/CT) to help doctors figure out whether suspicious spots in the body are actually cancer spread. Right now, when standard imaging shows unclear results, doctors often have to do biopsies or wait and watch. The medication helps the imaging scan highlight cancer cells more clearly, which could help avoid unnecessary procedures and guide treatment decisions.
When doctors scan for cancer spread, they sometimes find spots that could be cancer or could be something harmless—and it's hard to know without a biopsy. This trial exists to see whether this new treatment can help doctors answer that question more accurately, so fewer patients need invasive procedures.
You likely qualify if…
You likely don't qualify if…
You will receive two intravenous infusions—one is a standard antibody medication called , and the other is the experimental imaging tracer (89Zr ). After the infusions, you'll undergo a PET/CT scan, which is a type of imaging that combines a CT scan with a special camera to show where the tracer has traveled in your body. The scan helps doctors see which spots are most likely to be cancer. The study involves a one-time visit for these procedures; the total enrollment is 60 patients.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States